Dasatinib intermediair-1

Dasatinib intermediate-1 is an intermediate in the synthesis of Dasatinib. Dasatinib Is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity[1].

302964-08-5

12352005

H302, H315, H319, H335

Bcr-Abl

Protein Tyrosine Kinase/RTK

Cancer

98.0

O=C(C1=CN=C(NC2=NC(C)=NC(Cl)=C2)S1)NC3=C(C)C=CC=C3Cl

C16H13Cl2N5OS

394.28

H302, H315, H319, H335

[1]Distler JH, et al. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) . 2008 Oct;47 Suppl 5:v10-1.

Blue Ice

-20°C (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-41940/Dasatinib-intermediate-1-SDS-MedChemExpress.pdf

Reference compound1

No Development Reported